Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?
Mené sur 135 patients atteints d'un cancer colorectal HER2+ de stade avancé (durée médiane de suivi : 8,9 mois), cet essai multicentrique de phase II détermine la dose maximale tolérée du trastuzumab déruxtécan puis évalue son efficacité du point de vue du taux de réponse objective
In approximately 5% of patients with metastatic colorectal cancer, overexpression or amplification of HER2 is observed, with a higher incidence in left-sided RAS and BRAF wild-type tumours. HER2-positive metastatic colorectal cancer is one of the key molecularly distinct subgroups of colorectal cancer and might represent an oncotarget in this disease.
The Lancet Oncology 2023